Secreted heat shock protein gp96-Ig: Next-generation vaccines for cancer and infectious diseases

Natasa Strbo, Arlene Garcia-Soto, Taylor H. Schreiber, Eckhard R. Podack

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Over the past decade, our laboratory has developed a secreted heat shock protein (HSP), chaperone gp96, cell-based vaccine that generates effective anti-tumor and anti-infectious immunity in vivo. Gp96-peptide complexes were identified as an extremely efficient stimulator of MHC I-mediated antigen cross-presentation, generating CD8 cytotoxic T-lymphocyte responses detectable in blood, spleen, gut and reproductive tract to femto-molar concentrations of antigen these studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce both systemic and mucosal immunity. This approach takes advantage of the combined adjuvant and antigen delivery capacity of gp96 for the generation of cytotoxic immunity against a wide range of antigens in both anti-vial and anti-cancer vaccination. Here, we review the vaccine design that utilizes the unique property/ability of endoplasmic HSP gp96 to bind antigenic peptides and deliver them to antigen-presenting cells.

Original languageEnglish (US)
Pages (from-to)311-325
Number of pages15
JournalImmunologic Research
Volume57
Issue number1-3
DOIs
StatePublished - Dec 1 2013

    Fingerprint

Keywords

  • Cancer
  • Gp96
  • Heat shock proteins
  • HIV
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Immunology

Cite this